Genefron Ltd. a privately held Israeli company, specializes in the development and manufacturing of next generation, in-vitro, personalized and companion diagnostic applications, in autoimmune and acute viral infectious diseases.
The company was established in 2011 and utilized its first 4 years of intensive R&D to achieve its first proof of concept : predicting the interferon α treatment outcome in hepatitis C virus patients. The prediction accuracy reached 96% in liver biopsies.
Following this achievement Genefron has expanded its success to address chronic autoimmune diseases such as MS and RA. In addition Genefron has developed a Personalized Diagnostic Kits (PDK) used by pregnant to predict CMV transmission to fetus. All PDKs are CE marked and Israeli ministry of health approved (read more ….)
In Israel, Genefron is selling its RA kits through marketing company HMO’s covering approximately 70% of the total population. In addition, CMV transmission predicting tests are sold through a private certified lab.
Our Pipe Line
Genefron promising pipeline consists current on going clinical trials:
- PDK for predicting B cell depletion drugs for RA patients.
- PDK for predicting anti TNF treatments in psoriasis arthritis and ankylosing spondylitis.
- In addition, Genefron is developing new signatures / products in various stages in inflammatory bowel diseases as well as local viral disease.
The Leading Team
Mr. Yaniv Kotler (LLB, M.Sc.)
CEO & Founder
Experience: 16 year biotech entrepreneur, established biotechnology start-up (Kovax) sold it in 2018 to Phibro. Serving in various executive roles for 25 years.
Dr. Yoav Smith (Ph.D.)
Genomic data analysis unit Management, Hebrew University – Jerusalem
Experience: Specializing in genomic analysis, machine learning algorithms, big data analysis and bioinformatics. Specialized in analysis of various types of biological and clinical data using advanced computing tools .
Dr. Shlomo Pundak (PhD)
Experience: Analytics, drugs, medical device development and in IVD development and regulation. More than 35 years’ experience in the biotech industry in various leading companies.
Orit Kotler (B.A, M.A.)
Experience: 26 years in high tech/biotech, managed multi $ M projects in corporate and private companies. CEO of Kovax Ltd, sold to Phibro (2018).
The company has a firm IP which includes 1 granted (USA), 4 PCT, 1 provisional, jointly owned with Hebrew University, Israel